Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$97.01

0.46 (0.48%)

08:03
08/07/18
08/07
08:03
08/07/18
08:03

Celltrion applies for trials of AbbVie's Humira biosimilar CT-P17 to MHRA

Celltrion applied for the clinical trials for its adalimumab biosimilar, or CT-P17, as a rheumatoid arthritis therapeutic agent, to the Medicines and Healthcare Products Regulatory Agency, or MHRA, in the UK. Celltrion is set to launch phase 1 clinical trials for the safety and pharmacokinetic assessment of the adalimumab biosimilar in the UK. And Celltrion also conducts global phase 3 clinical trials in about 75 sites in eight nations in European region from August. It aims to complete phase 3 clinical trials by 2020. Abbvie's Humira, the original medicine of CT-P17, is a therapeutic biopharmaceutical for the treatment of rheumatoid arthritis, inflammatory bowel disease, psoriatic arthritis, ankylosing spondylitis, etc., and it recorded sales of about $18.4B in 2017. Celltrion has developed CT-P17 as a high-concentration formulation and thus differentiated it from the competitive biosimilars which are conducting clinical trials or have already been approved. Meanwhile, after completing clinical trials for CT-P17, Celltrion is set to maximize its market share in TNF-a inhibitor biosimilar markets under the strategy of diversifying its TNF-a inhibitors along with Remsima, already sharing 52%2 of the Europe's original medicine market, and CT-P13 SC which is undergoing clinical trials with the goal of obtaining approvals in 2019.

ABBV AbbVie
$97.01

0.46 (0.48%)

06/15/18
JEFF
06/15/18
NO CHANGE
JEFF
Buy
AbbVie removed from Franchise Pick list at Jefferies
Jefferies analyst Ian Hilliker removed AbbVie from his firm's Franchise Pick list but keeps a Buy rating on the shares with a reduced price target of $125. The stock "continues to have an attractive upside based on its valuation," Hilliker tells investors in a research note.
06/22/18
FBCO
06/22/18
NO CHANGE
Target $89
FBCO
Underperform
AbbVie most exposed to biosimilar risk, says Credit Suisse
Credit Suisse analyst Vamil Divan reiterated an Underperform rating on AbbVie after the FDA further ramped up its focus on biosimilars. In a research note to investors, Divan said he was "intrigued" by the FDA's decision to withdraw its September 2017 Draft Guidance focused on evaluating analytical similarity with biosimilars, and believes the agency will release "more reasonable" guidance in the coming months that will expedite the approval and uptake of biosimilars. AbbVie is most exposed to Biosimilar risk, Divan says, with Humira accounting for about 60% of its total net present value, and is cautious on AbbVie's outlook in front of biosimilar competition in the EU later this year and in the U.S. by 2023.
07/24/18
SBSH
07/24/18
NO CHANGE
SBSH
Buy
Citi says Myovant may have $102 upside if relugolix priced at parity to elagolix
After AbbVie (ABBV) and Neurocrine Biosciences (NBIX) announced that the FDA approved elagolix and Neurocrine said the list price has been set at $28 per day, Citi analyst Robyn Karnauskas noted that she currently models Myovant Sciences' (MYOV) relugolix priced at $10 per day. Modeling relugolix pricing at parity to elagolix and assuming a gross-to-net of 100% would lead to a fair value estimate for Myovant of $146, or the equivalent of $102 of upside from her current price target of $44, Karnauskas stated. The analyst, who models a split market between relugolix and elagolix in endometriosis, keeps a Buy rating on Myovant shares.
07/27/18
PIPR
07/27/18
NO CHANGE
Target $100
PIPR
Neutral
Worries about AbbVie's Humira keep Piper Jaffray on sidelines
Piper Jaffray analyst Christopher Raymond said he finds "little to quibble with" in AbbVie's Q2 report, but also noted that while its FY18 EPS guidance was raised, its revenue guidance actually came down slightly. Raymond, who continues to worry that consensus does not fully factor in the extent of ex-U.S. Humira pressure or the further pressure from co-pay accumulator programs in the U.S., prefers to stay on the sidelines and keeps a Neutral rating on the shares. He also lowered his price target on AbbVie to $100 from $105.

TODAY'S FREE FLY STORIES

LYV

Live Nation

$48.15

-0.53 (-1.09%)

17:46
08/17/18
08/17
17:46
08/17/18
17:46
Hot Stocks
Live Nation CFO discloses sale of 40K shares of common stock »

Live Nation CFO Elizabeth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$72.63

0.21 (0.29%)

, XLU

Utilities SPDR

$54.50

0.25 (0.46%)

17:40
08/17/18
08/17
17:40
08/17/18
17:40
General news
Week ending ETF Scorecard: Consumer Staples outperforms, Energy skids »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$72.63

0.21 (0.29%)

XLU

Utilities SPDR

$54.50

0.25 (0.46%)

IYR

DJ US Real Estate Index Fund

$83.16

0.765 (0.93%)

XLP

Consumer Staples Sector SPDR

$55.02

0.39 (0.71%)

XLY

Consumer Discretionary Sector SPDR

$112.51

0.11 (0.10%)

XLB

S&P Select Materials SPDR

$58.41

0.41 (0.71%)

XLF

Financial Select Sector

$28.16

0.055 (0.20%)

XLV

Health Care Select Sector SPDR

$91.12

0.33 (0.36%)

XLK

Technology Select Sector SPDR

$73.17

0.14 (0.19%)

XLI

Industrial Select Sector SPDR

$76.26

0.47 (0.62%)

GLD

SPDR Gold Trust

$112.12

1.01 (0.91%)

SLV

iShares Silver Trust

$13.93

0.16 (1.16%)

USO

United States Oil Fund

$13.70

0.065 (0.48%)

UNG

United States Natural Gas Fund

$24.18

0.295 (1.24%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$86.03

0.08 (0.09%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.97

0.11 (0.09%)

TLT

iShares 20+ Year Treasury Bond Fund

$120.99

0.16 (0.13%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.49

0.04 (0.04%)

SHY

iShares 1-3 Year Treasury Bond

$83.28

0.03 (0.04%)

IWD

iShares Russell 1000 Value

$126.16

0.6 (0.48%)

IWF

iShares Russell 1000 Growth

$150.80

0.27 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$112.12

1.01 (0.91%)

17:33
08/17/18
08/17
17:33
08/17/18
17:33
Hot Stocks
SPDR Gold Trust holdings fall to 772.24MT from 773.41MT »

This is the 5th…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDOT

Green Dot

$85.04

0.37 (0.44%)

17:30
08/17/18
08/17
17:30
08/17/18
17:30
Hot Stocks
Green Dot exec Dent sells 7,754 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SMSI

Smith Micro

$2.49

-0.01 (-0.40%)

17:17
08/17/18
08/17
17:17
08/17/18
17:17
Syndicate
Breaking Syndicate news story on Smith Micro »

Smith Micro files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDRA

ENDRA Life Sciences

$2.70

0.2 (8.00%)

17:14
08/17/18
08/17
17:14
08/17/18
17:14
Syndicate
Breaking Syndicate news story on ENDRA Life Sciences »

ENDRA Life Sciences files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$346.44

0.55 (0.16%)

17:10
08/17/18
08/17
17:10
08/17/18
17:10
Hot Stocks
Boeing awarded $152.5M U.S. Navy contract »

Boeing is awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$346.44

0.55 (0.16%)

17:09
08/17/18
08/17
17:09
08/17/18
17:09
Hot Stocks
Boeing awarded $217M Defense Department contract »

The Boeing Co has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$210.37

0.56 (0.27%)

17:08
08/17/18
08/17
17:08
08/17/18
17:08
Hot Stocks
L3 Technologies awarded $240M Defense Department contract »

L-3 Communications was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSGX

Histogenics

$2.65

-0.05 (-1.85%)

17:06
08/17/18
08/17
17:06
08/17/18
17:06
Syndicate
Breaking Syndicate news story on Histogenics »

Histogenics files $75M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLD

Prologis

$67.45

1.79 (2.73%)

, DCT

DCT Industrial

$68.77

1.805 (2.70%)

16:58
08/17/18
08/17
16:58
08/17/18
16:58
Conference/Events
DCT Industrial to host special shareholder meeting »

Special Shareholder…

PLD

Prologis

$67.45

1.79 (2.73%)

DCT

DCT Industrial

$68.77

1.805 (2.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLK

Westlake Chemical

$95.61

-1.33 (-1.37%)

16:56
08/17/18
08/17
16:56
08/17/18
16:56
Hot Stocks
Westlake Chemical expands share repurchase program by $150M »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 11

    Sep

SM

SM Energy

$27.38

0.17 (0.62%)

16:55
08/17/18
08/17
16:55
08/17/18
16:55
Recommendations
SM Energy analyst commentary at MUFG »

SM Energy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

PENN

Penn National

$33.04

0.86 (2.67%)

16:51
08/17/18
08/17
16:51
08/17/18
16:51
Hot Stocks
Penn National CEO acquires 100,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$173.78

-0.98 (-0.56%)

16:49
08/17/18
08/17
16:49
08/17/18
16:49
Periodicals
U.S. wants Facebook to help wiretap Messenger for criminal probe, Reuters says »

The U.S. government is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 22

    Aug

  • 06

    Sep

  • 18

    Sep

WLK

Westlake Chemical

$95.61

-1.33 (-1.37%)

16:46
08/17/18
08/17
16:46
08/17/18
16:46
Hot Stocks
Westlake Chemical raises quarterly dividend 19% to 25c per share »

The dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 11

    Sep

EAST

Eastside Distilling

$7.40

-0.01 (-0.13%)

16:45
08/17/18
08/17
16:45
08/17/18
16:45
Syndicate
Breaking Syndicate news story on Eastside Distilling »

Eastside Distilling files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOV

Spark Networks

$12.80

-0.095 (-0.74%)

16:44
08/17/18
08/17
16:44
08/17/18
16:44
Syndicate
Spark Networks files to sell 515,416 ordinary shares for holders »

Including 222 ordinary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AHPA

Avista Healthcare Public Acquisition Corp.

$10.12

(0.00%)

16:42
08/17/18
08/17
16:42
08/17/18
16:42
Hot Stocks
Avista Healthcare Public Acquisition Corp., Organogenesis announce combination »

Avista Healthcare Public…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCF

TCF Financial

$25.84

0.17 (0.66%)

16:41
08/17/18
08/17
16:41
08/17/18
16:41
Hot Stocks
TCF Financial COO sells 77,725 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGF.A

Lionsgate

$22.95

-0.11 (-0.48%)

16:38
08/17/18
08/17
16:38
08/17/18
16:38
Recommendations
Lionsgate analyst commentary at Barrington »

Lionsgate price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

16:35
08/17/18
08/17
16:35
08/17/18
16:35
General news
Breaking General news story  »

Moody's cuts Turkey…

MSL

MidSouth Bancorp

$14.90

0.1 (0.68%)

16:32
08/17/18
08/17
16:32
08/17/18
16:32
Hot Stocks
MidSouth Bancorp says 'will carefully review' letter sent by Jacobs Asset Mgt. »

MidSouth Bancorp issued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EME

EMCOR

$77.96

1.005 (1.31%)

16:31
08/17/18
08/17
16:31
08/17/18
16:31
Hot Stocks
Emcor CEO sells 23,434 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
08/17/18
08/17
16:30
08/17/18
16:30
Options
Preliminary option volume of 22.3M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.